Midazolam as Adjunct Therapy to Morphine to Relieve Dyspnea?

Journal of Pain and Symptom Management

Volumn 33, Issue 3, 2007, Pages 233-234

  Sironi, Orsola ^a   Sbanotto, Alberto ^a   Banfi, Maria Grazia ^a   Beltrami, Carmen ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM; MORPHINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; DRUG POTENTIATION; DYSPNEA; GENERAL CONDITION DETERIORATION; HUMAN; LETTER; OXYGEN SATURATION; OXYGEN THERAPY; TERMINALLY ILL PATIENT;

ANALGESICS, OPIOID; DRUG THERAPY, COMBINATION; DYSPNEA; HUMANS; HYPNOTICS AND SEDATIVES; MIDAZOLAM; MORPHINE; NEOPLASMS; PALLIATIVE CARE;

EID: 33947173301     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.12.001     Document Type: Letter

References (5)

1. Navigante A., and Cerchietti L. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 31 (2006) 38-47
2. Bruera E., and De Stoutz N. The effects of oxygen on the intensity of dyspnea in hypoxemic terminal cancer patients. Lancet 342 (1993) 13-14
3. Bruera E., Schoeller T., and MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized trial. J Pain Symptom Manage 7 6 (1992) 365-368
4. Bruera E. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 17 (2003) 659-663
5. Earle C. Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol 24 (2006) 838-840